Brazilian national surveillance recorded a peak in mortality and hospital admissions attributed to Severe Acute Respiratory Infection (SARI) between January and August 2025. The analysis summarized here used Ministry of Health records to describe temporal and age-specific changes in SARI outcomes across multiple viral causes from January 2023 through June 2025. The study emphasizes differences in trends among young children and older adults.
The author compiled Ministry of Health data on hospital admissions and deaths due to SARI, aggregated by age group (<5, 5–14, 15–49, 50–64, 65+ years) and by quarter for the period January 2023 to June 2025. SARI causes were grouped into four categories: SARS-CoV-2, Influenza, Respiratory Syncytial Virus (RSV), and a combined category of other respiratory viruses (parainfluenza, adenovirus, rhinovirus, bocavirus, metapneumovirus).
Where deaths lacked laboratory confirmation of etiology, the analysis used multinomial regression to impute likely causes. The results compared rates across quarters and years, with emphasis on changes observed in the second quarter of 2025 (2025/2) relative to prior comparable periods.
Key reported findings include the following age- and pathogen-specific changes observed through 2025 Q2:
Among children aged <5 years, the RSV mortality rate reached 60 per 100,000 in 2025 Q2; this represents a 43% increase compared with 2024 Q2 as reported by the source.
For the pooled category of parainfluenza, adenovirus, rhinovirus, bocavirus and metapneumovirus in children <5 years, mortality doubled on the reported scale from 20 to 40 per 100,000 in 2025 Q2 compared with 2024 Q2.
In the aged population, influenza mortality was reported to have tripled in 2025 Q2 relative to the prior period; the source does not provide absolute per-age-group counts for influenza in the abstract but emphasizes the large proportional increase.
Mortality attributed to other respiratory viruses increased less dramatically among older adults than influenza did, according to the report.
SARS-CoV-2 mortality among the aged declined markedly over the study interval, falling from 150 per 100,000 in 2023 Q1 to 25 per 100,000 by 2025 Q2.
The temporal pattern in hospital admissions largely mirrored the mortality trends across pathogens and age groups.
The report notes relative stability in other age groups (5–14, 15–49, 50–64) over the period covered.
All quantitative results cited above are reported in the source abstract. The full preprint is referenced for data details and supporting tables, and the author indicates that all data produced are available online at the URL cited in the references.
The analysis described in the preprint documents a rapid decline in SARS-CoV-2 mortality since 2023 alongside concurrent increases in mortality rates from other respiratory viruses, most notably RSV in children under five and influenza in older adults during 2025 Q2. Hospital admission trends reflected these mortality shifts.
The author concludes that public health actions to improve vaccine uptake against these infections should be prioritized. The source frames this as an urgent policy implication given the increases observed in the most vulnerable age groups.
Note that the article is a preprint and has not been peer reviewed; the author explicitly states this and cautions that findings should not be used to guide clinical practice without further evaluation.
The author declares that all data produced are available online at the referenced URL. The preprint includes statements confirming adherence to relevant ethical guidelines and that necessary institutional approvals, participant consent, and reporting checklists were followed. Details on the specific datasets, variable definitions, and code are indicated as available via the article's data/code links.
The source reports funding from the Conselho Nacional de Desenvolvimento Científico e Tecnológico (grant number 303552/2022-0). The author has declared no competing interests.